Somatostatin Analogues in Pharmacotherapy

de Herder, Wouter

doi:10.1002/9781119031659.ch15

Expression of somatostatin receptors (sst's) by endocrine tumors is essential for the control of hormonal hypersecretion and control of tumor growth by somatostatin analogues. The currently available somatostatin analogues, Octreotide and Lanreotide, bind with a high affinity to the sst subtypes sst2 and sst5. Pasireotide (SOM 230) is a somatostatin analogue that binds to all sst subtypes, except sst4.

Additional Metadata
Keywords	Acromegaly, Lanreotide, Neuroendocrine tumors, Octreotide, Pasireotide, Pharmacotherapy, Somatostatin, Somatostatin analogues
Persistent URL	doi.org/10.1002/9781119031659.ch15, hdl.handle.net/1765/98767
Rights	No subscription
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Herder, W. (2015). Somatostatin Analogues in Pharmacotherapy. In Somatostatin Analogues: From Research to Clinical Practice (pp. 166–168). doi:10.1002/9781119031659.ch15

See Also
article Somatostatin Analogues: From Research to Clinical Practice A. Hubalewska-Dydejczyk (Alicja), Signore, A. (Alberto), M. de Jong (Marion), R.A. Dierckx (Rudi), J. Buscombe (John) and C. Van de Wiele (Christophe)

Somatostatin Analogues in Pharmacotherapy

Publication

Publication

article
Somatostatin Analogues: From Research to Clinical Practice

About

Somatostatin Analogues in Pharmacotherapy

Publication

Publication

article Somatostatin Analogues: From Research to Clinical Practice

Workflow

Workflow

Add Content

article
Somatostatin Analogues: From Research to Clinical Practice